Presentation

Biovica: Committed to developing and commercializing novel blood-based biomarker assays.

Biovica is a Swedish biotech founded in 2009 with a vision to improve monitoring and predicting the efficacy of cancer therapies. The initial focus of Biovica is breast cancer, a disease responsible for over 600,000 deaths a year. Biovica work with leading cancer institutes, collaborative groups, and pharmaceutical companies on product development, with the aim of improving outcomes and lowering costs.

Clinical validation of DiviTum®, the company´s lead test, has been selected for support and funding by the European Commission Horizon 2020 phase 2 program.